Intended for the quantitative determination of magnesium in serum or plasma. Reaction: Endpoint. Wavelength: 520 nm. Linearity: 6.0 mg/dL (2.5 mmol/L).
For the quantitative determination of Magnesium in serum. Linearity: 4.0 mEq/L. Working Reagent prepared by simple 1:10 dilution.
For the quantitative determination of total glucose in serum.
Glucose reagent is used for the quantitative determination of glucose in human serum.
Medicine Products:(Date:10/15/2008)... TomoTherapy Incorporated (NASDAQ: TOM..., recently hosted a symposium on the clinical use ...iosurgery (SRS) and stereotactic body radiation th...iArt system’s inherent suitability for stere...ty and homogeneity; presented clinical work on a v...
(Date:10/15/2008)...ct. 15 /PRNewswire-FirstCall/ -- Affiliated Comput...he award of a $27 million, 21-month,contract for t...on System,(MMIS) for the state of Alaska,s Departm... October 2007, ACS signed a $130 million, 10-year ... and operate a new MMIS system.,Now, as part of a ...
(Date:10/15/2008)...a., Oct. 15 /PRNewswire-USNewswire/ -- Clinical Ca...nnovative online, print, and live,medical educatio...ment with,the American Association for the Study o...al provider of its unique Conference Coverage of A...n San Francisco, California,October 31 - November...
(Date:10/15/2008)... to help prevent a catastrophe of epic proportions...ho Pays for Your Health Care, NEW YORK, Oct. 15 /...elling and informative. His vision of, empowering...ology,having transparent costs, and integrating s... the system from one that fails to one that...
Breaking Medicine News(10 mins):Health News: Grupo IMO Hosts Symposium on Use of TomoTherapy for Stereotactic Radiosurgery and Stereotactic Body Radiation Procedures : Experts Detail HiArt Platform Advantages for Treatment of Brain, Lung, Pancreatic and Metastatic Cancers 2Health News: Grupo IMO Hosts Symposium on Use of TomoTherapy for Stereotactic Radiosurgery and Stereotactic Body Radiation Procedures : Experts Detail HiArt Platform Advantages for Treatment of Brain, Lung, Pancreatic and Metastatic Cancers 3Health News:ACS Signs $27 Million Contract with Alaska to Transition Fiscal Agent Services for State Medicaid Program 2Health News:ACS Signs $27 Million Contract with Alaska to Transition Fiscal Agent Services for State Medicaid Program 3Health News:American Association for the Study of Liver Diseases Enters Into Agreement With Clinical Care Options as Its Authorized Online Conference Coverage Provider for the Liver Meeting(R) 2008 2Health News:With the Economy of the United States at a Turning Point, Health Care Could Be Our Next Serious Crisis ... 2(Date:10/13/2008)...nding advances study Study needed because of...Oct. 13 /- Advanced Circulatory Syste...nounced today that it has received,an additional $...s of,Health (NIH) to continue a study testing two ...e cardiac arrest outside a hospital. Whatcom Count...
(Date:10/13/2008)... -- Neuronascent, Inc.,( http://www.neuronascent.c...,funding from multiple sources to further the deve...ng Alzheimer,s disease, depression and,ischemia. N...aryland,Department of Business and Economic Develo...trial Partnerships in collaboration with Universit...
(Date:10/13/2008)...gher Sensitivity and Specificity, than Other Rapi...ferred test in all phases of this ...wire/ -- AT First Diagnostic LLC an,emerging world...s, today,announced that a recent evaluation conduc...of the FirstVue(TM) HBSAG Test, was released at th...
(Date:10/13/2008)...Cancer Populations Facilitates ...3 /- Rubicon Genomics, Inc. today,ann... DNA samples for The,Cancer Atlas Genome Project.,...ndardize total genomic,DNA from 3,000 tissue and b...omePlex(TM) Whole Genome Amplification technology ...
Breaking Medicine Technology:Whatcom County, Washington Participating in NIH Study of Cardiac Arrest Resuscitation Techniques 2Neuronascent, Inc. Receives Multiple Fundings for Its Neurogenesis Therapeutic Programs 2Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 2Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 3Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 4Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project 2Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project 3Internews Enlists More Than 1 000 Journalists in Fight Against HIV AIDS 26261 1Internews Enlists More Than 1 000 Journalists in Fight Against HIV AIDS 26261 2Fitness Model Entrepreneur Targets Childhood Obesity and Makes Headlines Nationwide With New Franchise Offering 26259 1Fitness Model Entrepreneur Targets Childhood Obesity and Makes Headlines Nationwide With New Franchise Offering 26259 2Guardian Survey 3A Men are Twice as Likely as Women to Use Credit Cards to Pay for Major Health Expenses 26257 1Guardian Survey 3A Men are Twice as Likely as Women to Use Credit Cards to Pay for Major Health Expenses 26257 2Guardian Survey 3A Men are Twice as Likely as Women to Use Credit Cards to Pay for Major Health Expenses 26257 3Guardian Survey 3A Men are Twice as Likely as Women to Use Credit Cards to Pay for Major Health Expenses 26257 4Guardian Survey 3A Men are Twice as Likely as Women to Use Credit Cards to Pay for Major Health Expenses 26257 5Guardian Survey 3A Men are Twice as Likely as Women to Use Credit Cards to Pay for Major Health Expenses 26257 6Beckman Coulter Investor Events Second Half of 2008 7610 1Beckman Coulter Investor Events Second Half of 2008 7610 2...SINESS WIRE)--May 17, 2007 - Salix,Pharmaceuticals...of,18 investigator-initiated trials related to the... Disease Week(R) 2007, which will be,held May 19-2...largest and most prestigious meeting in the world ...re than 16,000 physicians,researchers and academi...
...SIS 301012 produced at least 45% additional,reduct...imally-tolerated lipid-lowering therapies, CARLSBA...Isis,Pharmaceuticals, Inc. announced updated resul... 301012 in patients with homozygous,familial hyper...ere,presented in March at the of Cardiology Annual...
Other Medicine Technology:Salix Pharmaceuticals Previews Digestive Disease Week 2007 2Salix Pharmaceuticals Previews Digestive Disease Week 2007 3Salix Pharmaceuticals Previews Digestive Disease Week 2007 4Salix Pharmaceuticals Previews Digestive Disease Week 2007 5Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients 2Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients 3Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients 4Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients 5